Skip to main content
Erschienen in:

29.06.2022 | Biologika

Was muss der Internist bei Patienten unter Biologikabehandlung beachten?

Infektionen und Autoimmunphänomene

verfasst von: Prof. Dr. Thomas Zander, Michael Hallek

Erschienen in: rheuma plus | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Biologika zur Beeinflussung des Immunsystems spielen in der Behandlung von Autoimmun- und Tumorerkrankungen eine wichtige Rolle. Durch den Einsatz dieser nebenwirkungsarmen und gut wirksamen Therapeutika hat sich die Behandlung deutlich verbessert, sodass es zu einem längeren therapeutischen Einsatz kommt. Daher spielen Nebenwirkungen in der ärztlichen Betreuung auch außerhalb der Primärbehandlung eine immer größere Rolle. Durch die immunsuppressiven bzw. immunmodulierenden Biologika steigt das Risiko von Infektionen mit typischen Erregern vor allem der oberen Atemwege und des Urogenitaltrakts. Aber auch Infektionen mit selteneren Erregern wie Pilzen oder Mykobakterien treten vermehrt auf. Unter immunverstärkenden Biologika treten an den verschiedensten Organen Autoimmunphänomene auf, die zunächst durch Pausierung der Therapie oder aber durch eine immunsuppressive Therapie behandelt werden können.
Literatur
1.
Zurück zum Zitat Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39:425–441CrossRef Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39:425–441CrossRef
2.
Zurück zum Zitat Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ (2011) Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 70:2119–2125CrossRef Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ (2011) Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 70:2119–2125CrossRef
3.
Zurück zum Zitat Nogid A, Pham DQ (2006) Role of abatacept in the management of rheumatoid arthritis. Clin Ther 28:1764–1778CrossRef Nogid A, Pham DQ (2006) Role of abatacept in the management of rheumatoid arthritis. Clin Ther 28:1764–1778CrossRef
4.
Zurück zum Zitat Winthrop KL, Mariette X, Silva JT et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24(Suppl 2):S21–S40CrossRef Winthrop KL, Mariette X, Silva JT et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24(Suppl 2):S21–S40CrossRef
5.
Zurück zum Zitat Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723CrossRef Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723CrossRef
6.
Zurück zum Zitat Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532CrossRef Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532CrossRef
7.
Zurück zum Zitat Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330CrossRef Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330CrossRef
8.
Zurück zum Zitat Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 381:1535–1546CrossRef Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 381:1535–1546CrossRef
9.
Zurück zum Zitat Demlova R, Valik D, Obermannova R, ZdraZilova-Dubska L (2016) The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors. Physiol Res 65:S455–S462CrossRef Demlova R, Valik D, Obermannova R, ZdraZilova-Dubska L (2016) The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors. Physiol Res 65:S455–S462CrossRef
11.
Zurück zum Zitat Hay KA, Hanafi LA, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T‑cell therapy. Blood 130:2295–2306CrossRef Hay KA, Hanafi LA, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T‑cell therapy. Blood 130:2295–2306CrossRef
12.
13.
Zurück zum Zitat Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188–195CrossRef Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188–195CrossRef
14.
Zurück zum Zitat Maggi E, Vultaggio A, Matucci A (2011) Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 7:55–63CrossRef Maggi E, Vultaggio A, Matucci A (2011) Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 7:55–63CrossRef
15.
Zurück zum Zitat Muraro A, Lemanske RF Jr., Castells M et al (2017) Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 72:1006–1021CrossRef Muraro A, Lemanske RF Jr., Castells M et al (2017) Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 72:1006–1021CrossRef
16.
Zurück zum Zitat Vultaggio A, Matucci A, Nencini F et al (2010) Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 65:657–661CrossRef Vultaggio A, Matucci A, Nencini F et al (2010) Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 65:657–661CrossRef
17.
Zurück zum Zitat Benucci M, Manfredi M, Saviola G, Baiardi P, Campi P (2009) Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. Clin Exp Rheumatol 27:333–336PubMed Benucci M, Manfredi M, Saviola G, Baiardi P, Campi P (2009) Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. Clin Exp Rheumatol 27:333–336PubMed
18.
Zurück zum Zitat Matucci A, Pratesi S, Petroni G et al (2013) Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 43:659–664PubMed Matucci A, Pratesi S, Petroni G et al (2013) Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 43:659–664PubMed
19.
Zurück zum Zitat Dupont B, Mariotte D, Clarisse B et al (2014) Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test. Future Oncol 10:2133–2140CrossRef Dupont B, Mariotte D, Clarisse B et al (2014) Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test. Future Oncol 10:2133–2140CrossRef
20.
Zurück zum Zitat Steinke JW, Platts-Mills TA, Commins SP (2015) The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol 135:589–596 (quiz 597)CrossRef Steinke JW, Platts-Mills TA, Commins SP (2015) The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol 135:589–596 (quiz 597)CrossRef
22.
Zurück zum Zitat Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011:CD8794PubMedCentral Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011:CD8794PubMedCentral
23.
Zurück zum Zitat Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A (2011) Effectiveness and safety of the interleukin 6‑receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 70:755–759CrossRef Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A (2011) Effectiveness and safety of the interleukin 6‑receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 70:755–759CrossRef
24.
Zurück zum Zitat Kaegi C, Wuest B, Schreiner J et al (2019) Systematic review of safety and efficacy of Rituximab in treating immune-mediated disorders. Front Immunol 10:1990CrossRef Kaegi C, Wuest B, Schreiner J et al (2019) Systematic review of safety and efficacy of Rituximab in treating immune-mediated disorders. Front Immunol 10:1990CrossRef
25.
Zurück zum Zitat Riedell P, Carson KR (2014) A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf 13:977–987CrossRef Riedell P, Carson KR (2014) A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf 13:977–987CrossRef
26.
Zurück zum Zitat Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ (2014) Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 53:1872–1885CrossRef Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ (2014) Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 53:1872–1885CrossRef
27.
Zurück zum Zitat Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP (2008) Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 83:181–194CrossRef Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP (2008) Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 83:181–194CrossRef
28.
Zurück zum Zitat Vallabhaneni S, Chiller TM (2016) Fungal infections and new biologic therapies. Curr Rheumatol Rep 18:29CrossRef Vallabhaneni S, Chiller TM (2016) Fungal infections and new biologic therapies. Curr Rheumatol Rep 18:29CrossRef
29.
Zurück zum Zitat Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563–580CrossRef Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563–580CrossRef
30.
Zurück zum Zitat Naidoo J, Page DB, Li BT et al (2015) Toxicities of the anti-PD‑1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375–2391CrossRef Naidoo J, Page DB, Li BT et al (2015) Toxicities of the anti-PD‑1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375–2391CrossRef
31.
Zurück zum Zitat Collins LK, Chapman MS, Carter JB, Samie FH (2017) Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 41:125–128CrossRef Collins LK, Chapman MS, Carter JB, Samie FH (2017) Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 41:125–128CrossRef
32.
Zurück zum Zitat Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P (2016) Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res 26:413–416CrossRef Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P (2016) Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res 26:413–416CrossRef
33.
Zurück zum Zitat Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95CrossRef Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95CrossRef
34.
Zurück zum Zitat Morganstein DL, Lai Z, Spain L et al (2017) Thyroid abnormalities following the use of cytotoxic T‑lymphocyte antigen‑4 and programmed death receptor protein‑1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86:614–620CrossRef Morganstein DL, Lai Z, Spain L et al (2017) Thyroid abnormalities following the use of cytotoxic T‑lymphocyte antigen‑4 and programmed death receptor protein‑1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86:614–620CrossRef
35.
Zurück zum Zitat Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T‑cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583–589CrossRef Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T‑cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583–589CrossRef
36.
Zurück zum Zitat Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356CrossRef Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356CrossRef
37.
Zurück zum Zitat Torino F, Corsello SM, Salvatori R (2016) Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 28:278–287CrossRef Torino F, Corsello SM, Salvatori R (2016) Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 28:278–287CrossRef
38.
Zurück zum Zitat Barroso-Sousa R, Barry WT, Garrido-Castro AC et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173–182CrossRef Barroso-Sousa R, Barry WT, Garrido-Castro AC et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173–182CrossRef
39.
Zurück zum Zitat Haanen J, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142CrossRef Haanen J, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142CrossRef
40.
Zurück zum Zitat Gupta A, De Felice KM, Loftus EV Jr., Khanna S (2015) Systematic review: colitis associated with anti-CTLA‑4 therapy. Aliment Pharmacol Ther 42:406–417CrossRef Gupta A, De Felice KM, Loftus EV Jr., Khanna S (2015) Systematic review: colitis associated with anti-CTLA‑4 therapy. Aliment Pharmacol Ther 42:406–417CrossRef
41.
Zurück zum Zitat Naidoo J, Wang X, Woo KM et al (2017) Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 35:709–717CrossRef Naidoo J, Wang X, Woo KM et al (2017) Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 35:709–717CrossRef
Metadaten
Titel
Was muss der Internist bei Patienten unter Biologikabehandlung beachten?
Infektionen und Autoimmunphänomene
verfasst von
Prof. Dr. Thomas Zander
Michael Hallek
Publikationsdatum
29.06.2022
Verlag
Springer Vienna
Erschienen in
rheuma plus / Ausgabe 5/2022
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI
https://doi.org/10.1007/s12688-022-00536-0

Weitere Artikel der Ausgabe 5/2022

rheuma plus 5/2022 Zur Ausgabe